Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia

Human Psychopharmacology

Volumn 24, Issue 3, 2009, Pages 225-232

  Henderson, David C ^a,b,c   Fan, Xiaoduo ^a,b   Copeland, Paul M ^b   Sharma, Bikash ^a   Borba, Christina P ^a   Forstbauer, Sharon I ^a   Miley, Kate ^a   Boxill, Ryan ^a   Freudenreich, Oliver ^a,b   Cather, Corrine ^a,b   Evins, Anne E ^a,b   Goff, Donald C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Freedom Trail Clinic   (United States)

Author keywords

Clozapine; Insulin resistance; Lipids; Olanzapine; Schizophrenia; Weight; Ziprasidone

Indexed keywords

CHOLESTEROL; CLOZAPINE; GLUCOSE; OLANZAPINE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; EDUCATIONAL STATUS; ETHNIC DIFFERENCE; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MALE; MORBIDITY; NEGATIVE SYNDROME; OBESITY; PRIORITY JOURNAL; QT INTERVAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT REDUCTION; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; HYPERGLYCEMIA; MIDDLE AGED; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CHRONIC DISEASE; CLOZAPINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; MORBIDITY; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES; TIME FACTORS;

EID: 67649746271     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1012     Document Type: Article

References (40)

1. Alao AO, Malhotra K, Dewan MJ. 2002. Comparing the side effect profile of the atypical antipsychotics. West Afr J Med 21: 313-315.
2. Allison DB, Mentore JL, Heo M, et al. 1999. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696.
3. Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. 2002. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 71: 244-254.
4. Baptista T, Kin NM, De Beaulieu S, Baptista EA, 2002. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35: 205-219.
5. Bymaster FP, Calligaro DO, Falcone JF, et al. 1996. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96.
6. Caro JJ, Ward A, Levinton C, Robinson K. 2002. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63: 1135-1139.
7. Cohen S, Fitzgerald B, Okos A, Khan S, Khan A. 2003. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry 64: 60-62.
8. Colli A, Cocciolo M, Francobandiera F, Rogantin F, Cattalini N. 1999. Diabetic ketoacidosis associated with clozapine treatment. Diabetes Care 22: 176-177.
9. Daniel DG, Copeland LF. 2000. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. Expert Opin Investig Drugs 9: 819-828.
10. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. 2007. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 92: 90-94.
11. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. 2002. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63: 920-930.
12. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. 1998. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 59: 294-299.
13. Hann DM, Denniston MM, Baker F. 2000. Measurement of fatigue in cancer patients: further validation of the Fatigue Symptom Inventory. Qual Life Res 9: 847-854.
14. Henderson D, Goff D. 1996. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 57: 395-397.
15. Henderson DC, Cagliero E, Gray C, et al. (2000a) Clozapine, diabetes mellitus, weight. gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157: 975-981.
16. Henderson DC, Cagliero E, Gray C, et al. (2000b) Clozapine, diabetes mellitus, weight. gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157: 975-981.
17. Henderson DC, Goff DC, Connolly CE, Borba CP, Hayden D. 2001. Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 62: 605-608.
18. Henderson DC, Cagliero E, Copeland PM, et al. 2005. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62: 19-28.
19. Henderson DC, Copeland PM, Borba CP, et al. (2006a) Glucose metabolism in patients with. schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 67: 789-797.
20. Henderson DC, Kunkel L, Nguyen DD, et al. (2006b) An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 113: 142-147.
21. Kato MM, Goodnick PJ. 2001. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother 2: 1571-1582.
22. Kay SR, Opler LA, Lindenmayer JP, 1987. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23: 99-110.
23. Kissebah A, Vydelingum N, Murry R, et al. 1982. Relationship of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54: 254-260.
24. Koller EA, Doraiswamy PM. 2002. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22: 841-852.
25. Koller E, Schneider B, Bennett K, Dubitsky G. 2001. Clozapine-associated diabetes. Am J Med 111: 716-723.
26. Kroeze WK, Hufeisen SJ, Popadak BA, et al. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526.
27. Melkersson KI, Hulting AL, Brismar KE. 2000. Elevated levels of insulin, leptin, and blood lipids in olanzapine- treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61: 742-749.
28. Millan MJ, Schreiber R, Dekeyne A, et al. 1998. S 16924 ((R)-2-[1-[2- (2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4- fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286: 1356-1373.
29. Newcomer JW, Haupt DW, Fucetola R, et al. 2002. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59: 337-345.
30. Opp D, Hildebrandt C. 2002. Olanzapine-associated type 2 diabetes mellitus. Schizophr Res 56: 195-196.
31. Pi-Sunyer FX. 1993. Medical hazards of obesity. Ann Intern Med 119: 655-660.
32. Reynolds GP, Zhang Z, Zhang X. 2003. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 160: 677-679.
33. Seaburg HL, Mclendon BM, Doraiswamy PM. 2001. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. Pharmacotherapy 21: 1448-1454.
34. Shapiro DA, Renock S, Arrington E, et al. 2003. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400-1411.
35. Spitzer RL, Williams JBW, Gibbon M, First MB, 1992. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 49: 624-629.
36. Spivak B, Alamy SS, Jarskog LF, Sheitman BB, Lieberman JA. 2002. Ziprasidone alternative for olanzapine-induced hyperglycemia. Am J Psychiatry 159: 1606.
37. Vickers SP, Clifton PG, Dourish CT, Tecott LH. 1999. Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl) 143: 309-3014.
38. Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. 2008. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 33: 985-994.
39. Wetterling T. 2001. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24: 59-73.
40. Wilson DR, D'souza L, Sarkar N, Newton M, Hammond C. 2003. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 59: 1-6.